Jeannie Joughin has also held various scientific positionsin Australia and internationally in Austria and Switzerland. Dr. Joughin beganher career in the pharmaceutical industry in 1992 as a Clinical ResearchManager with Bristol-Myers Squibb. After managing local trials in oncology andcardiology, she moved into New Product Commercialization as the interfacebetween the medical and marketing departments. From there, Dr. Joughin workedin various marketing and executive level business development roles. As VicePresident, Business Development at CSL Behring, Dr Joughin was responsible formanaging global business licensing arrangements and executed the deal with MikeHooven (CEO Enable Injections) to license the Enable Injections technology forCSL. Her passion for bringing the technology to users in therapeutic areasbeyond those serviced by CSL caused her to make the move to Cincinnati and leadlicensing for Enable Injections. Now as Vice President, Corporate DevelopmentJeannie Joughin is responsible for business development, strategic alliances,alliance management, marketing & clinical activities and will be integralin the selection and prioritization Enable’s global portfolio.

Enable Injections develops and manufactures devices thatallow patient self-administration of high volume/viscosity drugs. The EnableInjector technology is a discreet body-worn device that provides acomfortable injection experience allowing the patient to continue with normaldaily activities. The Enable system is designed to utilize any standardcontainer closure system, including a syringe or vial. Enable Injectionsis seeking to license its technology to biopharmaceutical companies andoptimize the delivery of subcutaneous combination products for various chronicand serious diseases.